Acadian Asset Management
MACK

Acadian Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Acadian Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-31,849
Closed -$174K – 2198
2019
Q1 		$174K Buy
31,849
+28,895
+978% +$133K ﹤0.01% 1390
2018
Q4 		$9K Buy
+2,954
New +$10.2K ﹤0.01% 1619

Other funds holding MACK

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Acadian Asset Management's MACK Position: Q2 2019 in Review

Acadian Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2019, closing a stake of 31,849 shares — an estimated $174K sold.

Acadian Asset Management first reported a position in MACK in Q4 2018 and held it in 2 quarters. The position peaked at $174K in Q1 2019. 50 funds tracked by Wall St. Rank hold MACK as of Q2 2019.

  • Acadian Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Acadian Asset Management sold 31,849 Merrimack Pharmaceuticals, Inc. shares in Q2 2019, an estimated $174K.
  • Acadian Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
  • Acadian Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $174K in Q1 2019.
  • 50 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2019.

Based on Acadian Asset Management's 13F filing for Q2 2019, filed 8 Aug 2019.